30.06.20 ijBio Portfolio
Infojet ClubPharm Involved.
$1,000,000 on 12.06.20 Changes for 30.06.20:
AstraZeneca (AZN) $51,3 $52,9 (+3.1%) $103,100
Inovio (INO) $13,2 $27 (+104,5%) $204,500
Moderna (MRNA)$61,5 $64,2 (+4.9%) $104,900
Abbot (ABT) $88,5 $91,4 (+3.3%) $103,300
Gilead (GILD) $72,5 $77 (+6.2%) $106,200
Adaptive (ADPT) $42,2. $48,4 (+14,7%) $114,400
CytoDyn (CYDY) $3,12 $5,68 (+82%) $182,000
AbbVie (ABBV) $92,2 $98,2 (+6.5%) $106,500
Arcus (RCUS) $27,3 $24,7 (-9,5%) $90,500
Sorrento (SRNE) $4,6 $6,3 (+36,9%) $136,900
At close 30.06.20=$1,252,700 (-7,9%)
per million dollars at 10% per share.
At close 29.06.20=$1,361,400 (+6,4%)
At close 26.06.20= $1,279,600
during the two weeks 12-26.06.2020:+28% and
during the week 19-26.06.2020:+21%
At close 19.06.20= $1,057,700
during the week 12-19.06 +6%
12.06.20 = $1,000,000
Global Communication Platforms portfoilio
--
Portfolio News:
My Top 5 Portfolio Holdings for the Second Half of 2020
Love Dividends? 3 Stocks You Might Want to Buy
This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines
Germany for now has enough remdesivir for COVID-19 therapy -govt
China's Sinopharm unit completes new COVID-19 vaccine plant, doubles capacity
South Korea to start talks on COVID-19 drug remdesivir purchases in August
US Indexes Close Higher on the Last Day of June
MS Global Franchise Fund's 1st-Quarter Portfolio
Why Inovio Pharmaceuticals Plunged 20% Today
How Risky Is Moderna Stock Right Now?
Biogen and Moderna shares show how biotech ETFs may look similar but act differently
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
Abbott, Tandem Diabetes Seal Deal on Diabetes Managemen
Benchmark analyst expects FDA to allow Inovio's coronavirus vaccine to move to Phase 2/3 clinical
Coronavirus update: Travel restrictions fly as Fauci issues grim warning on casualties
Top Marijuana Stocks on the NASDAQ for July 2020
Hedge Funds Dropped The Ball On Diodes Incorporated (DIOD)
3 Stocks With Low Forward Price-Earnings Ratios
FDA issues rules for coronavirus vaccine developer
Investors shouldn't chase a potential COVID-19 vaccine winner: Analyst
Inovio Pharmaceuticals Vaccine 'Deemed Safe' in Phase I Tes
Inovio Pharmaceuticals Reports Results From Phase 1 Clinical Trial of Coronavirus Vaccine Candidate
Inovio Presents ‘Positive’ Early Data For Covid-19 Vaccine Candidate; Shares Plunge 12
Why Inovio Pharmaceuticals Stock Is Sinking Today
Morning Bell With Jim Cramer: Buy Bristol-Myers, Not Gilead
Inovio’s Covid-19 Vaccine Shows Promise. Here’s Why Its Stock Is Down Anyway.
Nasdaq's $1.2 trln biotech index draws Europe's COVID drug hu
With help but without the assistance of Yahoo Finance
Advertise With Us